NEW YORK (GenomeWeb News) – KineMed today said that it and Bristol-Myers Squibb have extended a collaboration covering Alzheimer's disease and other neurodegenerative ailments.
Under the extension, KineMed is granting Bristol-Myers Squibb a non-exclusive license to KineMed's technology for the identification and characterization of AD biomarkers in cerebrospinal fluid.
Financial and other terms of the deal were not disclosed.
Based in Emeryville, Calif., KineMed calls itself a "dynamic proteomics" firm, using mass spectrometry to track stable isotopes to measure the rates of change in certain metabolic pathways that may be associated with disease.
"Understanding what is going on in the living brain is key to drug development in neurodegenerative diseases," said David Fineman, president and CEO of KineMed. By measuring fundamental brain process in a living person, "KineMed is enabling research on potential treatments that address the causes, rather than the symptoms of disease," he added.